½ÃÀ庸°í¼­
»óǰÄÚµå
1404753

°»³â±â Àå¾Ö ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Ä¡·áº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)

Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), By Region (North America, Europe, Latin America), And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°»³â±â Àå¾Ö ½ÃÀå ¼ºÀå ¹× µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°è Æó°æ±â ½ÃÀå ±Ô¸ð´Â 2024-2030³â°£ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 5.37%¸¦ ³ªÅ¸³»°í, 2030³â¿¡´Â 244¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Æó°æ ÈÄ ÁõÈıºÀÇ À¯º´·ü Áõ°¡, °»³â±â Àå¾Ö °ü·Ã °Ç°­ ÀÎ½Ä Áõ°¡, ¿©¼º °Ç°­ ¾ÛÀÇ ³ôÀº äÅ÷ü µîÀÌ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº HRT¿¡ ´ëÇÑ °Ç°­ º¸Á¶ ½ÄǰÀÇ ÀÌÁ¡À» µÞ¹ÞħÇÏ´Â ¿¬±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÁÖµµµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºí·¢ÄÚÈ£½Ã, ·¹µå Ŭ·Î¹ö, ´ëµÎ À̼ÒÇöóº», ¾Ïº£·» µîÀÇ ¼ººÐÀ» ÇÔÀ¯ÇÑ ¸¹Àº °Ç°­ º¸Á¶ ½ÄǰÀÌ ½ÃÁß¿¡ ³ª¿Í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéµµ °»³â±â Àå¾Ö Áõ»ó°ú °ü·ÃµÈ ½ÅÁ¦Ç°À» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¸ôÆÄ½º(Morphas)´Â 2023³â °»³â±â Àå¾Ö ¹× °»³â±â Àå¾ÖÀÇ °¡Àå ½É°¢ÇÑ Áõ»óÀ» ÇØ°áÇϱâ À§ÇØ ¸î °¡Áö º¸ÃæÁ¦ Á¦Ç°À» Ãâ½ÃÇß½À´Ï´Ù. ù ¹øÂ° Á¦Ç°Àº ±¸¾Æ ¼¶À¯·Î ¸¸µç ¹«ÇâÀÇ ¼ö¿ë¼º ÇÁ¸®¹ÙÀÌ¿Àƽ ¼¶À¯ÀÎ ÆÄÀ̹öÀ¯½º(FiberUs)ÀÔ´Ï´Ù.

¿µ¾ç º¸ÃæÁ¦ ¹× OTC ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä´Â ÀÇ»ç ¿¹¾à Áö¿¬, È£¸£¸ó ´ëü ¿ä¹ýÀÇ À翬±â, ¼Ò¸Å ¾à±¹ ¹× ¿Â¶óÀΠä³Î¿¡¼­ OTC ÀǾàǰÀ» ½±°Ô ±¸ÇÒ ¼ö ÀÖ°Ô µÊ¿¡ µû¶ó ÆÒµ¥¹Í ÀÌÈÄ ½Ã³ª¸®¿À¿¡¼­ Áõ°¡Çß½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ ¿ÏÈ­¿Í °»³â±â Àå¾Ö¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀåÀº ÇöÀç ¾ÈÁ¤È­µÇ°í ÀÖ½À´Ï´Ù.

¿­°¨°ú ½ÄÀº¶¡À» Ä¡·áÇϱâ À§ÇÑ ÀǾàǰÀÇ FDA ½ÂÀÎÀÌ ±ÞÁõÇϰí ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î, 2023³â 5¿ù FDA´Â Æó°æ±â¿¡ °³ÀÎÀÌ ÈçÈ÷ °æÇèÇÏ´Â ½ÄÀº¶¡°ú ¾È¸éÈ«Á¶¸¦ Ä¡·áÇÏ´Â »õ·Î¿î ºñÈ£¸£¸ó ¾à¹°À» ½ÂÀÎÇß½À´Ï´Ù. ÆäÁ¹¸®³×ÀÌÆ®(Fesolinertan)¶ó°í ºÒ¸®´Â ÀÌ Ã³¹æ¾àÀº È£¸£¸ó Ä¡·á¸¦ ¹ÞÀ» ¼ö ¾ø°í À¯¹æ¾Ï »ýÁ¸ÀÚ µî Ç÷°ü ¿îµ¿ Áõ»óÀ¸·Î °íÅë¹Þ´Â »ç¶÷µéÀ» À§ÇØ Æ¯º°È÷ °í¾ÈµÆ½À´Ï´Ù. ÀÌ ¾àÀº Veozah¶ó´Â ºê·£µå·Î ÆÇ¸ÅµÇ°í ÀÖ½À´Ï´Ù.

°»³â±â Àå¾Ö ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • Ä¡·á¹ý¿¡ µû¸£¸é, 2023³â¿¡´Â ¿µ¾ç º¸ÃæÁ¦ Ä¡·á ºÎ¹®ÀÌ ½ÃÀåÀ» Àå¾ÇÇÏ°í ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀº ³ëÀÎ Àα¸ Áõ°¡¿Í Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 4¿ù Çѱ¹ÀÇ °Ç°­±â´É½Äǰ ±â¾÷ Ç®¹«¿øÀº °»³â±â Àå¾Ö °ü·Ã Áõ»ó Ä¡·á¸¦ À§ÇØ Äá°ú È© ÃßÃâ¹°À» ÇÔÀ¯ÇÑ Á¦Ç°À» Ãâ½ÃÇß½À´Ï´Ù.
  • OTC ÀǾàǰ Ä¡·á ºÎ¹®Àº ºñÈ£¸£¸ó Á¦Ç°°ú È£¸£¸ó Á¦Ç°À¸·Î ³ª´¹´Ï´Ù. °»³â±â Àå¾Ö ¿©¼ºµéÀº ÀϹÝÀǾàǰ(OTC) È£¸£¸ó Á¦Ç°À» ´õ ¸¹ÀÌ »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ ÁÖ¿ä Á¦Ç°À¸·Î´Â ±¹¼Ò ÇÁ·Î°Ô½ºÅ×·Ð, À̺ÎÇÁ·ÎÆæ, µðÇÏÀ̵å·Î¿¡ÇǾȵå·Î½ºÅ×·Ð(DHEA), ¸á¶óÅä´Ñ µîÀÌ ÀÖ½À´Ï´Ù.
  • 2023³â ºÏ¹Ì°¡ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ½Ä»ýȰ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ ³ëÀÎ ¿©¼ºµé »çÀÌ¿¡¼­ ƯÁ¤ ¿µ¾ç ¿ä±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • Amyris, Inc.´Â 2022³â 1¿ù °»³â±â Àå¾Ö Ä¡·á, ¿©¼º °Ç°­ ¿¬±¸, °»³â±â Àå¾Ö¿¡ ´ëÇÑ »çȸÀû ÀÌÇØ ÁõÁø¿¡ ÁÖ·ÂÇÏ´Â ¿©¼º â¾÷ ±â¾÷ MenoLabs, LLCÀÇ ÀÚ»êÀ» µ¶Á¡ÀûÀ¸·Î ÀμöÇÏ´Â °è¾àÀ» ü°áÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.
  • 2023³â 1¿ù, ¿©¼º °Ç°­ ºê·£µå ¿ÀÆ÷ÁöƼºê´Â °»³â±â Àå¾Ö ¿©¼ºµéÀÌ Æí¸®ÇÏ°í ¸ÀÀÖ´Â ¹æ¹ýÀ¸·Î Áõ»óÀ» °ü¸®ÇÒ ¼ö ÀÖµµ·Ï »ç»ó ÃÖÃÊÀÇ °»³â±â Àå¾Ö ±¸¹Ì ºñŸ¹ÎÀ» Ãâ½ÃÇß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­¿Í ¹üÀ§
  • ½ÃÀå °èÅë Àü¸Á
    • »óÀ§ ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå µ¿Çâ°ú Àü¸Á
  • ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • »ç¾÷ ȯ°æ ºÐ¼®
    • PESTLE ºÐ¼®
    • PorterÀÇ Five Forces ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå Ä¡·á ºñÁî´Ï½º ºÐ¼®

  • °»³â±â Àå¾Ö ½ÃÀå : Ä¡·á º¯µ¿ ºÐ¼®
  • ½ÄÀ̺¸ÃæÁ¦
  • OTC ÀǾàǰ
    • È£¸£¸ó Á¦Ç°
    • ºñÈ£¸£¸ó Á¦Ç°

Á¦5Àå Áö¿ª ºñÁî´Ï½º ºÐ¼®

  • Áö¿ªº° °»³â±â Àå¾Ö ½ÃÀå Á¡À¯À², 2023³â & 2030³â
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
    • µ§¸¶Å©
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
    • ÀμöÇÕº´(M&A)
    • Çù¾÷
    • ½ÅÁ¦Ç° ¹ß¸Å
  • Âü¿© ±â¾÷ °³¿ä
    • Bayer AG
    • Theramex
    • Abbvie Inc.
    • Abbott
    • Pure Encapsulations, LLC
    • Dr. Reddy's Laboratories Ltd.
    • Rainbow Light
    • PADAGIS LLC
LSH 24.01.23

Menopause Market Growth & Trends:

The global menopause market size is expected to reach USD 24.4 billion by 2030, registering a CAGR of 5.37% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is expected to be driven by factors such as rising prevalence of post-menopausal syndrome, increasing awareness regarding menopause-associated health aspects, and high adoption of women's health apps.

The market is projected to be driven by rising research supporting the benefits of dietary supplements over HRT. Many dietary supplements are available in the market that contain ingredients such as black cohosh, red clover, soy isoflavones, and amberen. Manufacturers are also involved in developing new products to address menopausal symptoms. For instance, Morphus launched several supplement products in 2023 to address some of the most pressing symptoms of menopause and perimenopause. The first product launched was FiberUs, an unflavored soluble prebiotic fiber made from guar fiber.

The demand for dietary supplements and OTC pharma products increased in the post-pandemic scenario due to the delays in physician's appointments, rescheduling of hormonal replacement therapies, and the easy availability of OTC drugs from retail pharmacies and online channels. However, the market is now stabilizing due to the ease of restrictions and the increasing awareness of menopause.

The surge in FDA approvals for drugs aimed at treating hot flashes and night sweats is a significant factor propelling the growth of the market. In May 2023, the FDA gave their approval for a new non-hormonal medication to address night sweats and hot flashes that are often experienced by individuals during menopause. This prescription drug, called fezolinetant, is specifically designed for those who are unable to take hormonal therapy and who are struggling with vasomotor symptoms, such as breast cancer survivors. The medication is branded under the name Veozah.

Menopause Market Report Highlights:

  • Based on treatment, the dietary supplements treatment segment dominated the market in 2023 and is expected to witness the fastest growth during the forecast period. The growth of the segment can be attributed to several factors, including the increasing geriatric population and the launch of innovative products. For instance, in April 2021, Pulmuone, a South Korea-based dietary supplement firm, introduced a product that contains soybean and hop extracts for the treatment of menopause-related symptoms
  • The OTC pharmaceutical products treatment segment is categorized into non-hormonal and hormonal products. Women undergoing menopause are increasingly using over-the-counter (OTC) hormone products. Major products in this segment include topical progesterone, ibuprofen, Dehydroepiandrosterone (DHEA), and melatonin
  • North America held the largest revenue share in 2023. There is a growing awareness about dietary requirements, which is leading to a greater demand among older women for specific nutritional needs
  • In January 2022, Amyris, Inc. announced that it has entered into exclusive agreements to acquire the assets of a women-founded company MenoLabs, LLC. that focuses on treating menopause symptoms, conducting research of women's health and increasing society's understanding of menopause
  • In January 2023, O Positiv, a women's health brand, launched the first-ever menopause gummy vitamin, providing menopausal women with a convenient and tasty way to manage their symptoms

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. Gvr's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Growing number of women undergoing menopause
    • 3.4.2. Increasing awareness about menopause and its treatment
    • 3.4.3. Growing opportunities and innovations in menopause treatment
    • 3.4.4. Increasing research supporting advantages of dietary supplements
  • 3.5. Market Restraint Analysis
    • 3.5.1. Social stigma associated with menopause and adverse effects of products
    • 3.5.2. Lack of well-defined regulations
  • 3.6. Business Environment Analysis
    • 3.6.1. PESTLE Analysis
    • 3.6.2. Porter's Five Forces Analysis
  • 3.7. COVID-19 Impact Analysis

Chapter 4. Treatment Business Analysis

  • 4.1. Menopause Market: Treatment Movement Analysis
  • 4.2. Dietary Supplements
    • 4.2.1. Dietary Supplements Market, 2018 - 2030 (USD Million)
  • 4.3. OTC Pharma Products
    • 4.3.1. OTC Pharma Products Market, 2018 - 2030 (USD Million)
    • 4.3.2. Hormonal Products
      • 4.3.2.1.1. Hormonal Products Market, 2018 - 2030 (USD Million)
    • 4.3.3. Non-hormonal Products
      • 4.3.3.1.1. Non-hormonal Products Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. Menopause Market Share By Region, 2023 & 2030
  • 5.2. North America
    • 5.2.1. North America Menopause Market, 2018 - 2030 (USD Million)
    • 5.2.2. U.S.
      • 5.2.2.1. Key Country Dynamics
      • 5.2.2.2. Regulatory Framework/Scenario
      • 5.2.2.3. Competitive Scenario
      • 5.2.2.4. U.S. Menopause Market, 2018 - 2030 (USD Million)
    • 5.2.3. Canada
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Regulatory Framework/Scenario
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Canada Menopause Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. Europe Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.2. UK
      • 5.3.2.1. Key Country Dynamics
      • 5.3.2.2. Regulatory Framework/Scenario
      • 5.3.2.3. Competitive Scenario
      • 5.3.2.4. Germany Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.3. Germany
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Regulatory Framework/Scenario
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. UK Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.4. France
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Regulatory Framework/Scenario
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. France Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.5. Italy
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Regulatory Framework/Scenario
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Italy Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.6. Spain
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Regulatory Framework/Scenario
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Spain Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.7. Sweden
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Regulatory Framework/Scenario
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Sweden Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.8. Norway
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Regulatory Framework/Scenario
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Norway Menopause Market, 2018 - 2030 (USD Million)
    • 5.3.9. Denmark
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Regulatory Framework/Scenario
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Denmark Menopause Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. Asia Pacific Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.2. Japan
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Regulatory Framework/Scenario
      • 5.4.2.3. Competitive Scenario
      • 5.4.2.4. Japan Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.3. China
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Regulatory Framework/Scenario
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. China Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.4. India
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Regulatory Framework/Scenario
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. India Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.5. Australia
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Regulatory Framework/Scenario
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Australia Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.6. Thailand
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Regulatory Framework/Scenario
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Thailand Menopause Market, 2018 - 2030 (USD Million)
    • 5.4.7. South Korea
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Regulatory Framework/Scenario
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. South Korea Menopause Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. Latin America Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.2. Brazil
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Regulatory Framework/Scenario
      • 5.5.2.3. Competitive Scenario
      • 5.5.2.4. Brazil Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.3. Mexico
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Regulatory Framework/Scenario
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Mexico Menopause Market, 2018 - 2030 (USD Million)
    • 5.5.4. Argentina
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Regulatory Framework/Scenario
      • 5.5.4.3. Competitive Scenario
      • 5.5.4.4. Argentina Menopause Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. MEA Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.2. South Africa
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Regulatory Framework/Scenario
      • 5.6.2.3. Competitive Scenario
      • 5.6.2.4. South Africa Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.3. Saudi Arabia
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Regulatory Framework/Scenario
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Saudi Arabia Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.4. UAE
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Regulatory Framework/Scenario
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. UAE Menopause Market, 2018 - 2030 (USD Million)
    • 5.6.5. Kuwait
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Regulatory Framework/Scenario
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Kuwait Menopause Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
    • 6.2.1. Merger& Acquisition
    • 6.2.2. Collaborations
    • 6.2.3. New Product Launch
  • 6.3. Participant's overview
    • 6.3.1. Bayer AG
      • 6.3.1.1. Overview
      • 6.3.1.2. Financial Performance
      • 6.3.1.3. Product Benchmarking
      • 6.3.1.4. Strategic Initiatives
    • 6.3.2. Theramex
      • 6.3.2.1. Overview
      • 6.3.2.2. Financial Performance
      • 6.3.2.3. Product Benchmarking
      • 6.3.2.4. Strategic Initiatives
    • 6.3.3. Abbvie Inc.
      • 6.3.3.1. Overview
      • 6.3.3.2. Financial Performance
      • 6.3.3.3. Product Benchmarking
      • 6.3.3.4. Strategic Initiatives
    • 6.3.4. Abbott
      • 6.3.4.1. Overview
      • 6.3.4.2. Financial Performance
      • 6.3.4.3. Product Benchmarking
      • 6.3.4.4. Strategic Initiatives
    • 6.3.5. Pure Encapsulations, LLC
      • 6.3.5.1. Overview
      • 6.3.5.2. Financial Performance
      • 6.3.5.3. Product Benchmarking
      • 6.3.5.4. Strategic Initiatives
    • 6.3.6. Dr. Reddy's Laboratories Ltd.
      • 6.3.6.1. Overview
      • 6.3.6.2. Financial Performance
      • 6.3.6.3. Product Benchmarking
      • 6.3.6.4. Strategic Initiatives
    • 6.3.7. Rainbow Light
      • 6.3.7.1. Overview
      • 6.3.7.2. Financial Performance
      • 6.3.7.3. Product Benchmarking
      • 6.3.7.4. Strategic Initiatives
    • 6.3.8. PADAGIS LLC
      • 6.3.8.1. Overview
      • 6.3.8.2. Financial Performance
      • 6.3.8.3. Product Benchmarking
      • 6.3.8.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦